| Citation: | Fei LIANG. Why a P value <0.05 does not necessarily mean statistical significance: controversy over overall survival results of the ORIENT-11 trial[J]. Clinical Cancer Bulletin, 2022, 1(1): 47-48. doi: 10.11910/j.issn.2791-3937.2022.20220003
|
| [1] |
Oncologic Drugs Advisory Committee (ODAC) Meeting. FDA website. Accessed February 20, 2022. (https://bit.ly/3Bdwluu)
|
| [2] |
Singh H, Vellanki P. Sintilimab for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Presented at: Oncologic Drugs Advisory Committee (ODAC) Meeting February 10, 2022
|
| [3] |
Yang Y, Sun J, Wang Z, et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol, 2021, 16: 2109–20.
|
| [4] |
Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med, 2016, 375: 1823-1833.
|
| [5] |
Pai-Scherf L, Blumenthal GM, Li H, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist, 2017, 22: 1392–9
|
| [6] |
Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry. January 2017 (https://www.fda.gov/media/102657/download).
|
| [7] |
European Medicines Agency. Guideline on multiplicity issues in clinical trials. December 2016 (https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf).
|
| [8] |
Harrington D, D’Agostino RB, Gatsonis C, et al. New guidelines for statistical reporting in the Journal. N Engl J Med, 2019, 381(3): 285–286.
|
| [9] |
Hellmann MD, Paz-Ares L, Berbabe Caro R, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med, 2019, 381: 2020–31.
|
| [10] |
Dmitrienko A, D’Agostino RB Sr. Multiplicity considerations in clinical trials. N Engl J Med, 2018, 378: 2115-22.
|
| [11] |
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018, 378: 2078-2092.
|
| [12] |
Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol, 2020, 38: 2369–79.
|
Supported by: Beijing Renhe Information Technology Co. Ltd
DownLoad: